Zevra Therapeutics (ZVRA) shares soared 9.1% in the last trading session to close at $8.27. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 7.2% gain over the past four weeks. Last week, Zevra won the FDA approval for arimoclomol as an orally delivered treatment for Niemann-Pick disease type C (NPC). The drug will be marketed under the brand name, Miplyffa, in the United States for this indication. This marked a milestone achieve ...